Dr. Vacchiano, JD, PhD, analyzed the complex factual, regulatory and legal issues specifically related to Amarin's possible attempt to obtain a preliminary injunction from the court to stop a possible at-risk launch by Hikma of its generic Vascepa product. The ~10 page article includes concise conclusions with supporting analysis that is a must-read for Amarin investors and analysts so they better appreciate the complexities and uncertainties in the current situation. The article provides factual, legal, and even speculatory insights from an experienced biotech patent attorney, for a fraction of the typical cost for this level of analysis*.
The article focuses on analyzing how likely it is that Amarin would succeed in obtaining a preliminary injunction enjoining Hikma's possible at-risk generic product launch. Other questions addressed in the article including the following:
1) Is it likely that Hikma will execute an at-risk launch of its generic icosapent ethyl capsule product?
2) Can Amarin file a preliminary injunction motion now, and if so how likely are they to file such a motion?
4) What factors affect Amarin's chances of success in obtaining a preliminary injunction?
*Please note that your purchase of this article does NOT establish an attorney-client relationship between you and/or your company/firm/fund and Dr. Vacchiano or his law firm, Double Helix Law. You are encouraged to seek advice from your regulatory, legal, and investment advisors before making any investment decisions.